Importance Young adults (YAs; ages 18-39 years) diagnosed with cancer face unique psychosocial challenges, including high distress and poor health-related quality of life (HRQOL). There are few efficacious interventions tailored to their needs. Objective To evaluate the efficacy of Bright IDEAS-YA, a problem-solving skills training intervention tailored for YAs, in reducing distress and improving HRQOL. Design, Setting, and Participants This randomized clinical trial was conducted at 3 academic medical centers and enrolled participants between February 2021 and March 2024. Eligible participants were aged 18 to 39 years, within 4 months of a first cancer diagnosis, and undergoing systemic therapy. Participants completed surveys at baseline and 3, 6, 12, and 24 months. Intervention Bright IDEAS-YA is a 6-session, one-on-one intervention that teaches a structured approach to problem-solving. Enhanced usual care (EUC) included standard psychosocial care plus a list of adolescent and YA resources. Main Outcomes and Measures Primary outcomes were depression and anxiety (Patient-Reported Outcomes Measurement Information System Short Forms) and HRQOL (Functional Assessment of Cancer Therapy-General) at 6 months. Problem-solving ability (Social Problem-Solving Inventory-Revised Short Form) was examined as a mediator. Analyses used linear mixed effects models and mediation analysis. Results Of the 1128 YAs screened, 344 YAs (median [IQR] age, 31.27 [25.78-36.38] years; 251 female [62.5%]) enrolled, with 171 allocated to intervention and 173 allocated to control. Overall, 296 YAs (86.0%) and 280 YAs (81.4%) completed 3- and 6-month surveys, respectively. At 6 months, the intervention group showed significantly greater improvements than EUC in depression (effect size estimate, −3.23 points; 95% CI, −4.93 to −1.53 points; P < .001), anxiety (effect size estimate,−2.43 points; 95% CI, −4.05 to −0.81 points; P = .003), and HRQOL (effect size estimate, 3.40 points; 95% CI, 0.34 to 6.45 points; P = .03). These changes were clinically meaningful. Mediation analyses showed that improvements in depression and anxiety were partially due to increased problem-solving ability, particularly reductions in negative problem orientation. Sex and education were moderators of treatment effect, with the treatment effect on anxiety being greater for males (effect size estimate, −5.29 points; 95% CI, −7.97 to −2.60 points) and the treatment effect on anxiety (effect size estimate, −6.94 points; 95% CI, −10.50 to −3.43 points) and depression (effect size estimate, −7.47 points; 95% CI, −11.20 to −3.74 points; P < .001) being greater for those with lower education. Conclusions and Relevance In this randomized clinical trial of Bright IDEAS-YA, intervention participants had significantly reduced distress and improved HRQOL relative to control. These findings suggest that Bright IDEAS-YA may be offered as supportive care for YAs with cancer to improve psychosocial outcomes. Trial Registration ClinicalTrials.gov Identifier: NCT04585269
Results of a multisite randomized trial of Bright IDEAS-Young Adults: Efficacy of problem-solving skills training on distress and health-related quality of life.
12005 Background: Young adults (YAs) diagnosed with cancer between the ages of 18 and 39 face unique psychosocial challenges and are at risk of experiencing significant emotional distress and poor health-related quality of life (HRQOL). This randomized trial evaluated the efficacy of Bright IDEAS-YA, a problem-solving skills training intervention, on reducing distress and improving HRQOL of YAs newly diagnosed with cancer. A secondary aim examined change in problem-solving ability as a potential mediator of treatment effects. Methods: A three-site randomized trial of Bright IDEAS-YA compared with enhanced usual care (EUC) enrolled YA survivors within four months of a first diagnosis of cancer. Participants were randomized 1:1 to Bright IDEAS-YA or EUC (NCT04585269). Bright IDEAS-YA is a 6-session, one-on-one intervention that teaches a systematic approach to overcome personal challenges across any life domain. EUC involved usual psychosocial care plus AYA resources. Participants completed surveys at 0 (baseline), 3, 6, 12, and 24 months, with 6 months as the primary endpoint. Validated measures included the PROMIS Depression Short Form and Anxiety Short Form (primary outcomes), the Functional Assessment of Cancer Therapy – General (FACT-G; primary outcome), and Social Problem-Solving Inventory-Revised Short Form (SPSI-R; mediator). Efficacy was tested using linear mixed effects models, run in R, examining the group x time interaction effects. Mediation was tested using the R multiple mediation analysis. Results: 344 YA (34.2% acceptance rate, M age = 30.3 years, SD = 6.3; 63% female, 37% male, < 1% non-binary) participated (100% planned enrollment), with 86% and 81% completing surveys at 3 and 6 months, respectively. Compared to baseline, the intervention arm showed statistically significant improvements in depression, anxiety, and HRQOL relative to the control group at 6 months. The intervention arm demonstrated an average reduction of 3.2 T-score points reduction in depression (95% CI [-4.9, -1.5], p < 0.001), 2.4 T-score points in anxiety (95% CI [-4.0, -0.81], p = 0.003), and 3.4 points improvement in total FACT-G (95% CI [0.34, 6.5], p = 0.029) relative to the control. These differences reflect clinically meaningful changes per published reports. Across all three models, change in total problem-solving ability (SPSI-R) was shown to mediate treatment effects, primarily due to change in the negative problem-orientation subscale. Conclusions: Bright IDEAS-YA was efficacious in reducing symptoms of depression and anxiety and improving HRQOL compared with enhanced usual care among YAs with cancer. Improvements are attributable to increased problem-solving ability, particularly by reducing the tendency to view problems as significant threats and doubt one’s ability to successfully solve problems. Clinical trial information: NCT04585269 .
Abstract SS2-01: Impact of the COVID-19 pandemic on the multidisciplinary management of breast cancer: Initial analysis of the american society of breast surgeons mastery COVID-19 registry
Abstract Background: The COVID-19 pandemic rapidly altered health care worldwide. To save protective equipment and minimize exposures, many hospitals stopped some or all cancer surgery, leading oncologic providers to quickly adjust patient management. The goal of this study is to describe the breast cancer patient level changes which occurred during the initial months of COVID-19 in the United States. Methods: The American Society of Breast Surgeons developed a COVID-19 specific registry, within the established HIPPA compliant Mastery of Breast Surgery Program. Surgeons entered patient demographic data as well as their surgical and medical care (Neoadjuvant endocrine (NET) vs Neoadjuvant chemotherapy (NCT)). Data fields tracked whether decisions were usual for that practice, or modified due to COVID-19. Results: Between 3/1 and 6/17/2020, data from 1781 patients was entered by 154 surgeons. Mean age was 63, 78% Caucasian, 10% African American, 6% Hispanic; with geographic distribution ranging from 10.8% Northwest to 29.5% Northeast. Initial consultation took place in-person for 94.8% and only 5.2% (89) occurred via video/telephone. To date, just over 1% (14) of patients tested positive for COVID-19. Mean invasive tumor size was 21.2mm and 15.7% were node positive. Of 1445 invasive breast cancers 75% (1081) were ER +/HER2-, 13.5% (195) HER2+, 11.1% (160) triple negative (TNBC) (9/missing data). DCIS comprised 18.2% (325) of the cohort. Of 267 cases of ER+ DCIS, 49% (131) had primary surgery and 49% (130) received NET. The majority of NET use was due to COVID-19, 95% (124). Almost all (50/52) ER- DCIS underwent primary surgery (6/missing ER). Table 1 describes the management for the 1436 patients with invasive cancer with known biomarkers. NET due to COVID-19 was utilized in 45% (482), with only 5% (54) as part of usual practice. Increasing age was not a statistically significant factor in the use of NET (OR 0.99, 95% CI 0.97-1.01). In comparison to patients from the Northwest, patients from the Southwest and Northeast had the greatest use of NET(COVID-19) vs NET(usual) (ORs 14.4 and 4.6) Genomic assay testing was performed on the core biopsy in 216 patients, with 65% (141) due to COVID-19. Among the patients who had genomic testing due to COVID-19, 116 (82%) had NET, 18 (13%) had NCT, with the remaining having primary surgery. Of 472 patients treated with primary surgery for which the impact of COVID-19 was provided, surgery was delayed in 20% (96). Patients from the Northeast had a 2.1 x greater odds of having surgery delayed in comparison to those from the Midwest. Patients also experienced changes to their surgical plan with the most common changes being 6% (27) converting from mastectomy to breast conservation and 7% (34) from mastectomy with reconstruction to mastectomy without reconstruction. Conclusion: COVID-19 led to significant modifications in breast cancer treatment, including high rates of NET, genomic assay testing on core biopsies as well as delays in surgery; each of which were consistent with the prioritization and treatment recommendations from the COVID-19 Pandemic Breast Cancer Consortium. The majority of patients with TNBC and HER2+ disease received guideline concordant NCT. The ASBrS Mastery COVID-19 registry provides a snapshot into the rapid care changes caused by the pandemic, has ongoing data entry and analysis and will enable understanding of the impact on long term breast cancer outcomes. Table 1: Biomarker specific treatmentsER+/HER2- (1081)TNBC (160)HER2+/any ER (195)Mean Age656159African American (%)97(9%)21(13%)27(14%)Primary Surgery (usual)386 (36%)50 (31%)37 (19%)Primary Surgery (COVID-19)28 (2.6%)6 (3.7%)6 (3.1%)NET (usual)54 (5%)NA1(0.5%)NET (COVID-19)482 (45%)NA6 (3.6%)NCT (usual)90 (8.3%)98 (61%)137 (70%)NCT (COVID-19)39 (3.6%)6 (3.7%)8 (4.1%) Citation Format: Lee Gravatt Wilke, Toan T Nguyen, Qiuyu Yang, Bret M Hanlon, Kathryn A Wagner, Pamela Strickland, Eric A Brown, Jill Dietz, Judy C Boughey. Impact of the COVID-19 pandemic on the multidisciplinary management of breast cancer: Initial analysis of the american society of breast surgeons mastery COVID-19 registry [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr SS2-01.